(Q33343262)

English

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Yukio Kobayashi

object named as

Y Kobayashi

2

0 references

author name string

T Igarashi

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Ogura

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

T Kinoshita

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

T Ohtsu

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Y Sasaki

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Y Morishima

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

T Murate

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Kasai

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

N Uike

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Taniwaki

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Y Kano

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K Ohnishi

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Y Matsuno

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Nakamura

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Mori

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Y Ohashi

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K Tobinai

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

IDEC-C2B8 Study Group in Japan

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

1 June 2002

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

928-943

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Monoclonal antibody against PRAD1/cyclin D1 stains nuclei of tumor cells with translocation or amplification at BCL-1 locus

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Immunohistochemical analysis of cyclin D1 protein in hematopoietic neoplasms with special reference to mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Phase I study of the combination of monthly carboplatin and weekly cisplatin

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Non-Hodgkin's lymphomas of follicular center cell type in Osaka, Japan

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Practical utility of the revised European-American classification of lymphoid neoplasms for Japanese non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Malignant lymphoma in Hawaii-Japanese: a retrospective morphologic survey.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF155

21 January 2018

Identifiers

10.1093/ANNONC/MDF155

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33343262&oldid=1603836407"